🔒 IP News Bulletin for Japan and China, June 2026
China's NMPA issued Implementation Measures for Drug Trial Data Protection, introducing up to 6-year data exclusivity for innovative drugs.
High impact 20 min
Drug profile · INN
tak-
tak- is an FDA-listed pharmaceutical active ingredient.
NMPA: clinical trials
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tak-
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.70
Quick answer
tak- is an FDA-listed pharmaceutical active ingredient.
Key facts
INN tak-
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Related research
🔒 
🔒 The ICAOS, effective since 2002, replaced the 1937 Interstate Compact for Probation and Parole (ICPP) and serves as binding federal law gove…
High impact 308 min
A26 Informational Reports: Insights for Pharma Stakeholders
Total grants and donations received by the AMA in 2025 amounted to $3,666,000, supporting various public health initiatives.
High impact 300 min
Frequently asked questions
What is tak-?
tak- is an FDA-listed pharmaceutical active ingredient.